ARHGEF11 Antibody

What is the biological function of ARHGEF11 protein?

ARHGEF11 functions as a specific guanine nucleotide exchange factor (GEF) for RhoA, serving as a critical regulator of actin cytoskeleton dynamics and organization of dendritic spines. It has been identified as an inhibitor of spine maintenance in neuronal cells . Beyond neuronal functions, ARHGEF11 mediates RhoA-myosin light chain signaling pathways at cell-cell junctions, functioning in cooperation with ZO-1 to regulate epithelial barrier integrity . Additionally, ARHGEF11 has been implicated in promoting tumor metastasis in glioblastoma and ovarian carcinoma .

What are the standard applications for ARHGEF11 antibody?

The ARHGEF11 antibody (30508-1-AP) has been validated for multiple experimental applications including Western Blot (WB), Immunohistochemistry (IHC), and ELISA. For Western blotting, the recommended dilution range is 1:500-1:2000, while for IHC applications, dilutions between 1:50-1:500 are suggested . Each application requires proper optimization depending on the specific experimental system, and researchers should titrate the antibody concentration to achieve optimal results for their particular sample type.

What is the molecular weight of ARHGEF11 and how does this affect antibody detection?

While the calculated molecular weight of ARHGEF11 is 168 kDa, the observed molecular weight in experimental systems typically ranges between 200-220 kDa . This discrepancy is important to consider when interpreting Western blot results. The higher observed molecular weight may be attributed to post-translational modifications such as phosphorylation or glycosylation. Researchers should be aware of this difference when identifying ARHGEF11 bands on Western blots to avoid misinterpreting results.

How can ARHGEF11 antibody be used to study synaptic localization and function?

For synaptic localization studies, researchers can leverage the finding that ARHGEF11 interacts and colocalizes with both synaptophysin (presynaptic marker) and PSD-95 (postsynaptic marker) at synapse sites . Methodologically, subcellular fractionation followed by immunoblotting with ARHGEF11 antibody can verify its enrichment in synaptosomal fractions (P2) containing pre- and postsynaptic density proteins. Co-immunoprecipitation experiments using ARHGEF11 antibody can confirm interactions with synaptic proteins like synaptophysin and PSD-95. For visualization, immunofluorescence staining of primary cortical neurons (ideally at 28 DIV) will show ARHGEF11 localization in dendrites and dendritic spines, colocalizing with synaptic markers .

How can ARHGEF11 antibody be used to investigate epithelial-mesenchymal transition (EMT)?

ARHGEF11 has been implicated in epithelial-mesenchymal transition, a process associated with renal interstitial fibrosis development. To study this phenomenon, researchers can utilize ARHGEF11 antibody in combination with markers of EMT. The experimental approach should include assessment of RhoA activity levels (using pull-down assays), quantification of Rho-ROCK pathway activation (phospho-specific antibodies), and evaluation of EMT markers such as Col1a3, Mmp9, Bmp7, Ocln, N-Cadherin, and Vimentin . ARHGEF11 antibody can be used to track expression changes in different cell states and to correlate ARHGEF11 levels with EMT progression in disease models.

What methodological approaches can be used to study ARHGEF11's role in cell junction integrity?

To investigate ARHGEF11's function at cell-cell junctions, researchers can employ several techniques using ARHGEF11 antibody. First, co-immunoprecipitation with ZO-1 can confirm their direct interaction in your specific cell system . For functional studies, calcium switch assays combined with immunofluorescence can evaluate junction assembly dynamics. ARHGEF11 antibody can be used alongside phospho-MLC antibodies to assess activation of downstream signaling at different timepoints after calcium restoration. Researchers should analyze junction formation kinetics by staining for E-cadherin, ZO-1, and ARHGEF11 at multiple timepoints (2h, 6h, 24h post-calcium switch). Quantification of perijunctional actomyosin ring (PJAR) formation using phalloidin staining with ARHGEF11 co-labeling provides insights into its role in junctional cytoskeleton organization .

What are the optimal sample preparation methods for detecting ARHGEF11 in different experimental systems?

For Western blot detection of ARHGEF11, sample preparation varies by source:

For immunohistochemistry, antigen retrieval is crucial: mouse colon tissue requires TE buffer pH 9.0, though citrate buffer pH 6.0 can serve as an alternative . For brain sections, use shorter fixation times (maximum 15 minutes in 4% PFA) to preserve epitope accessibility. When performing IHC on kidney samples to study ARHGEF11 in epithelial cells, minimal fixation is recommended, and specimens should be processed promptly to maintain tissue morphology while preserving antigen recognition.

How should experiments be designed to investigate ARHGEF11 and the Rho-ROCK signaling pathway?

To effectively study ARHGEF11's role in Rho-ROCK signaling, design experiments that measure pathway activity at multiple levels. Begin by assessing ARHGEF11 expression and localization using the antibody in immunofluorescence and Western blot analyses. Follow with RhoA activity assays using GST-RBD pulldown methods to quantify active RhoA levels. Use phospho-specific antibodies to measure downstream effectors, particularly phosphorylated myosin light chain (p-MLC), which is significantly affected by ARHGEF11 depletion .

For functional validation, include positive and negative controls:

• Positive control: Constitutively active RhoA expression

• Negative control: ROCK inhibitor (fasudil) treatment or ARHGEF11 knockdown

To establish causality, combine these approaches with genetic manipulation of ARHGEF11 using siRNA knockdown or CRISPR-Cas9 editing, followed by rescue experiments with wild-type or mutant ARHGEF11 constructs resistant to the knockdown strategy.

What controls are essential when using ARHGEF11 antibody for quantitative analysis?

When performing quantitative analysis with ARHGEF11 antibody, several controls are critical:

For densitometric analysis of Western blots, always work within the linear range of detection and include a standard curve of recombinant protein or serially diluted positive control samples to ensure quantitative accuracy.

How can nonspecific background be reduced in ARHGEF11 immunohistochemistry?

Nonspecific background is a common challenge when performing ARHGEF11 immunohistochemistry. To reduce background:

• Optimize blocking conditions: Extend blocking time to 2 hours at room temperature using 5% normal serum from the same species as the secondary antibody.

• Adjust antibody dilution: For ARHGEF11 antibody, begin with the recommended 1:50-1:500 range but perform a dilution series to determine optimal concentration for your specific tissue .

• Antigen retrieval optimization: For mouse colon tissue, TE buffer pH 9.0 is recommended, but other tissues may require different conditions. Compare multiple retrieval methods (heat-induced vs. enzymatic) and buffers (citrate pH 6.0 vs. TE pH 9.0) to determine optimal conditions .

• Include additional blocking steps: For tissues with high endogenous peroxidase activity, include a 10-minute treatment with 3% hydrogen peroxide before the protein block step.

• Reduce antibody incubation temperature: Incubate primary antibody at 4°C overnight rather than at room temperature to increase specificity of binding.

What strategies can resolve inconsistent ARHGEF11 Western blot results?

Inconsistent Western blot results with ARHGEF11 antibody may stem from several factors:

• Protein degradation: ARHGEF11 is a large protein (observed at 200-220 kDa) that may be susceptible to degradation . Use fresh samples, keep them cold throughout processing, and include multiple protease inhibitors in lysis buffers.

• Transfer efficiency: Large proteins transfer poorly from gel to membrane. Use low percentage gels (6-8%), extend transfer time or use specialized transfer systems for high molecular weight proteins, and verify transfer with reversible staining.

• Antibody incubation conditions: For ARHGEF11, extend primary antibody incubation to overnight at 4°C at 1:1000 dilution in 5% BSA to improve consistent detection.

• Sample preparation variability: Standardize lysis procedures, including consistent cell confluence for cultured cells and rapid processing for tissue samples to minimize protein modifications or degradation.

• Membrane type selection: Use PVDF membranes with 0.45 μm pore size rather than 0.2 μm or nitrocellulose for better retention and detection of high molecular weight ARHGEF11.

How can researchers distinguish between specific and non-specific bands when detecting ARHGEF11?

Distinguishing specific ARHGEF11 bands from non-specific signals requires several validation approaches:

• Verify molecular weight: The specific ARHGEF11 band should appear between 200-220 kDa, though the calculated molecular weight is 168 kDa . This discrepancy may reflect post-translational modifications.

• Use positive controls: Include lysates from HEK-293T cells, HuH-7 cells, MDA-MB-453 cells, or mouse brain tissue, which have been validated for ARHGEF11 detection .

• Implement knockdown validation: Compare samples with ARHGEF11 knockdown (siRNA or shRNA) alongside control samples; specific bands should show reduced intensity in knockdown samples.

• Perform peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to the membrane; specific bands should disappear or be significantly reduced.

• Use fractionation controls: In subcellular fractionation experiments, ARHGEF11 should be enriched in synaptosomal fractions (P2) along with synaptophysin and PSD-95 when analyzing neuronal tissues , providing another specificity verification approach.

How should researchers interpret ARHGEF11 expression differences between normal and pathological states?

When analyzing ARHGEF11 expression differences between normal and pathological states, researchers should consider several key factors:

• Baseline expression context: ARHGEF11 is normally expressed in multiple tissues including brain, where it localizes to dendritic spines and interacts with both pre- and post-synaptic proteins . Any comparison should account for this normal distribution pattern.

• Quantification methodology: Changes in expression should be quantified using both protein levels (Western blot) and localization patterns (immunofluorescence/IHC), as ARHGEF11 function may be altered by subcellular redistribution without total protein changes. This was observed in ZO-1 knockout cells, where ARHGEF11 levels remained unchanged but localization was significantly disrupted .

• Functional correlation: Mere expression changes should be correlated with functional outcomes by measuring:

  • RhoA activity levels using pull-down assays

  • Downstream signaling through p-MLC quantification

  • Phenotypic consequences like cytoskeletal reorganization or EMT marker expression

• Tissue-specific considerations: In kidney pathology, increased ARHGEF11 expression correlates with enhanced RhoA activity and upregulation of Rho-ROCK signaling, promoting epithelial-mesenchymal transition . In neural tissue, ARHGEF11 overexpression negatively regulates dendritic spine formation .

How can researchers reconcile contradictory findings regarding ARHGEF11 function across different experimental systems?

Contradictory findings regarding ARHGEF11 function across experimental systems can be reconciled through several approaches:

• Context-dependent signaling analysis: ARHGEF11 may exhibit different functions depending on cellular context. In neurons, it negatively regulates dendritic spine formation , while in epithelial cells, it mediates RhoA-myosin light chain signaling at cell-cell junctions . These differences aren't contradictory but reflect tissue-specific roles.

• Protein interaction network mapping: ARHGEF11 interacts with different partners in different systems. In neurons, it binds synaptophysin and PSD-95 , while in epithelial cells, it interacts with ZO-1 . Comprehensively mapping these interactions helps explain functional diversity.

• Isoform and variant consideration: Genetic variants of ARHGEF11 can influence function, as seen in the Dahl salt-sensitive rat model where variants promote kidney injury through altered RhoA signaling . Researchers should verify which isoform or variant they're studying and consider how genetic differences might explain contradictory findings.

• Temporal dynamics assessment: ARHGEF11's role may vary based on developmental stage or disease progression. Time-course experiments examining ARHGEF11 function at different points can reconcile apparently contradictory snapshot observations.

• Cross-validation using complementary techniques: For example, conflicting results between overexpression and knockdown studies should be validated using pharmacological approaches (like ROCK inhibitors) to confirm the signaling pathway involvement.

What considerations are important when analyzing ARHGEF11 co-localization with binding partners?

When analyzing ARHGEF11 co-localization with binding partners, researchers should consider several methodological and interpretational factors:

• Resolution limitations: Standard confocal microscopy has a resolution limit of ~200nm, which may be insufficient to distinguish between true molecular interaction and mere proximity. Consider super-resolution techniques (STED, STORM, PALM) for more definitive co-localization analysis.

• Quantitative co-localization metrics: Rather than relying on visual assessment, use quantitative measures:

  • Pearson's correlation coefficient: Measures linear correlation between fluorescence intensities

  • Mander's overlap coefficient: Quantifies the fractional overlap between channels

  • Object-based co-localization: Counts discrete structures that contain both signals

• Verification through biochemical interaction: Co-localization should be verified by complementary techniques such as co-immunoprecipitation, as demonstrated for ARHGEF11's interaction with ZO-1 and synaptic proteins like synaptophysin and PSD-95 .

• Subcellular compartment context: ARHGEF11 shows distinct localization patterns in different cellular compartments. In ZO-1-knockout cells, ARHGEF11 shifts from tight junctions to a cytoplasmic distribution with a punctate pattern . This redistribution fundamentally changes the interpretation of co-localization with other junctional proteins.

• Functional validation of observed co-localization: Proximity doesn't necessarily indicate functional interaction. Observed co-localization should be validated through functional assays, such as measuring RhoA activity or MLC phosphorylation when ARHGEF11-partner interactions are disrupted.